WACKER to Invest Double-Digit Million-Euro Sum in Biotechnology Center

“The WACKER Biotechnology Center will allow us to concentrate and intensify our research activities in the area of biotechnology. The additional capacity we will create here will accelerate the growth of our life-sciences division,” WACKER CEO Christian Hartel said about the construction project. As part of its strategy for growth, the company is planning to significantly increase investment in the biotechnology sector in the coming years. The product portfolio is to expand through innovation, partnerships and acquisitions. By the year 2030, WACKER BIOSOLUTIONS plans to contribute around €1 billion to Group sales. The construction of the WACKER Biotechnology Center, in which the company is investing a double-digit million-euro amount, will aid this strategy.

The Biotechnology Center will be built in Munich, at the location of the Consortium für elektrochemische Industrie (WACKER’s corporate research facility). WACKER has been conducting fundamental research here for over 100 years and in the field of biotechnology since the 1980s. The growth of biotech business has stretched the capacity available for research activities to its limits. The Biotechnology Center, with space for around 90 employees, is intended to alleviate this. The foundation stone was laid today for the building, whose commissioning is planned for 2024.